ClinicalTrials.gg
RecruitingNCT07307404Updated Dec 29, 2025

Web-based Platform for Nutrition Management in Patients With Cancer

An interventional study of nutrtion care based on app in Nutrition, sponsored by Xingchen Peng. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Xingchen Peng · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

It is crucial to promptly identify nutritional issues in these patients within the community and provide them with dietary guidance, nutritional counseling, and support. This study will be conducted in communities in Chengdu, Sichuan. Community management teams will register oncology patients, collecting information such as demographic data, tumor type, stage, specific treatment plan, treatment hospital, regularity of hospital admissions, and frequency of independent smartphone use. Registered patients will be screened based on inclusion and exclusion criteria. For those who meet the criteria, the community management team will contact them and recommend the use of a dedicated app developed by the research team. An initial nutritional assessment will also be conducted. Patients identified with nutritional risks will be directly referred to the research team's clinical nutritionists for face-to-face consultations. After additional tests, such as body composition analysis, necessary nutritional education and stepwise nutritional interventions will be provided. These patients will also use the app for dietary monitoring and nutritional guidance. For patients without nutritional risks, the app will be recommended for daily questionnaire completion and activity tracking.

02

Conditions studied

  • Nutrition

Browse trials for

Keywords

  • cancer
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 84 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Xingchen Peng is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed malignant tumor;
  • PG-SGA score of 4-9 points;
  • Age: ≥18 years, with an expected survival time of more than 1 year;
  • Possesses adequate cognitive and reading abilities to complete questionnaires and use the APP.

Exclusion criteria

Exclusion Criteria:

  • Presence of neurological or psychiatric disorders affecting cognitive function, including central nervous system of tumors;
  • Suffering from conditions severely impacting digestion, metabolism, or food intake;
  • Patients in the cachexia stage or cachexia phase.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    intervention group

    Self-Intervention: During the period of staying at home, patients use the app developed by the team for self-intervention, including dietary monitoring and check-ins, nutritional risk assessment, learning of educational knowledge, and online expert consultations. Community Intervention: When nutritional risks are detected, pop-up alerts will notify patients to communicate with the community management team. Patients can seek basic nutritional consultations and receive advice from the community management team. If necessary, the management team will refer patients to relevant higher-level hospital outpatient clinics for further care. If patients experience other issues related to their primary condition, the community management team will refer them to community healthcare providers for consultation and treatment. The community will also organize thematic lectures on nutritional management for cancer patients, with oncologists and nutritionists providing regular voluntary consultatio

    Other: nutrtion care based on app

  • No intervention
    standard care

    standard nutrtion care

Interventions

  • Othernutrtion care based on app

    Self-Intervention: During the period of staying at home, patients use the app developed by the team for self-intervention, including dietary monitoring and check-ins, nutritional risk assessment, learning of educational knowledge, and online expert consultations. Community Intervention: When nutritional risks are detected, pop-up alerts will notify patients to communicate with the community management team. Patients can seek basic nutritional consultations and receive advice from the community management team. If necessary, the management team will refer patients to relevant higher-level hospital outpatient clinics for further care. If patients experience other issues related to their primary condition, the community management team will refer them to community healthcare providers for consultation and treatment. The community will also organize thematic lectures on nutritional management for cancer patients, with oncologists and nutritionists providing regular voluntary consultation

06

What researchers measure

Primary outcomes

  1. body weight change

    change of body weight during the trail

    Time frame: baseline, pre-intervention;every 2 weeks after randomization until 6 moths.

Secondary outcomes

  1. PG-SGA

    assessed using the PG-SGA score

    Time frame: baseline, pre-intervention;every 2 weeks after randomization until 6 moths.

  2. NRS2002

    using nutrition risk screening \[NRS 2002\]

    Time frame: baseline, pre-intervention;every 2 weeks after randomization until 6 moths.

Other outcomes

  1. EORTC QLQ C30

    using Quality-of-Life Questionnaire Core 30

    Time frame: baseline, pre-intervention;every 4 weeks after randomization until 6 moths.

  2. caregiver burden

    using the 12-Item Zarit Burden Interview \[ZBI\]

    Time frame: baseline, pre-intervention;every 4 weeks after randomization until 6 moths.

  3. psychology characteristics

    Hospital Anxiety and Depression Scale \[HADS\]

    Time frame: baseline, pre-intervention;every 4 weeks after randomization until 6 moths.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Oct 2026, 10 months later.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 10 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 29, 2025
StartEst.
Dec 30, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07307404
Lead sponsor
Xingchen Peng
Responsible party
Xingchen Peng (PhD, Professor, West China Hospital) — Sponsor-investigator
First posted
Dec 29, 2025
Start date
Dec 30, 2025 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Xingchen Peng
Contact
pxx2014@163.com
18980606753

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion